Daniel H. Shu
Impact in
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
-
- Hormonal Regulation and Hypertension
- Diabetes Treatment and Management
Papers in
- Oncology 6
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 1
-
- Immunotherapy and Immune Responses 3
- Immune Cell Function and Interaction 1
- interferon and immune responses 1
- Co-authors
- Mark M. Yarchoan (5 shared papers)Luciane Tsukamoto Kagohara (2 shared papers)Elizabeth M. Jaffee (2 shared papers)Jian Yan (1 shared paper)Thomas Urban Marron (1 shared paper)John M. Lyle (1 shared paper)Neil S. Cooch (1 shared paper)Josette M. Northcott (1 shared paper)
- Journals
- Diabetes Care (2 papers)Vaccine (1 paper)Nature Immunology (1 paper)Nature Medicine (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- United StatesSwitzerlandBelgium
In The Last Decade
Daniel H. Shu
18 papers receiving 788 citations
Daniel H. Shu's Hit Papers
Peers
Comparison fields: 5 of 66
- Hepatology 85
- Endocrinology, Diabetes and Metabolism 155
- Immunology 184
- Nephrology 43
- Oncology 155
Countries citing papers authored by Daniel H. Shu
This map shows the geographic impact of Daniel H. Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Shu more than expected).
Fields of papers citing papers by Daniel H. Shu
This network shows the impact of papers produced by Daniel H. Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Shu. The network helps show where Daniel H. Shu may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel H. Shu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial Hit paper breakdown → | 2024 | 172 |
| 2 | Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis Hit paper breakdown → | 2022 | 167 |
| 3 | 2024 | 71 | |
| 4 | 2023 | 61 | |
| 5 | 2016 | 59 | |
| 6 | 2024 | 51 | |
| 7 | 2017 | 47 | |
| 8 | 2022 | 45 | |
| 9 | 2022 | 30 | |
| 10 | 2011 | 29 | |
| 11 | 2023 | 27 | |
| 12 | 2025 | 17 | |
| 13 | 2025 | 8 | |
| 14 | 2025 | 7 | |
| 15 | 2024 | 5 | |
| 16 | 2012 | 3 | |
| 17 | 2022 | 3 | |
| 18 | 2025 | 1 |
About Daniel H. Shu
Daniel H. Shu is a scholar working on Oncology, Immunology, Epidemiology, Endocrinology, Diabetes and Metabolism and Biophysics, having authored 18 papers that have together received 803 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (3 papers), Respiratory viral infections research (2 papers), Influenza Virus Research Studies (2 papers), Immune Cell Function and Interaction (1 paper), interferon and immune responses (1 paper), CAR-T cell therapy research (1 paper) and Cytomegalovirus and herpesvirus research (1 paper). The work is most often cited by research in Hepatology (85 citations), Endocrinology, Diabetes and Metabolism (155 citations), Immunology (184 citations), Nephrology (43 citations) and Oncology (155 citations). Daniel H. Shu has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include Mark M. Yarchoan, Luciane Tsukamoto Kagohara, Elizabeth M. Jaffee, Jian Yan, Thomas Urban Marron, John M. Lyle, Neil S. Cooch, Josette M. Northcott, Jason T. Connor and Alfredo Perales‐Puchalt. Their work appears in journals such as Diabetes Care, Vaccine, Nature Immunology, Nature Medicine and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.